{"id":"NCT00336492","sponsor":"Centocor, Inc.","briefTitle":"A Study of the Safety and Efficacy of Infliximab(REMICADE ) in Pediatric Patients With Moderately to SeverelyActive Ulcerative Colitis","officialTitle":"A Phase 3, Randomized, Open-label, Parallel-group, Multicenter Trial to Evaluate the Safety and Efficacy of Infliximab (REMICADEï¿½) in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-09","primaryCompletion":"2009-05","completion":"2010-04","firstPosted":"2006-06-13","resultsPosted":"2011-08-10","lastUpdate":"2013-07-30"},"enrollment":60,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Ulcerative Colitis"],"interventions":[{"type":"BIOLOGICAL","name":"infliximab","otherNames":[]},{"type":"BIOLOGICAL","name":"infliximab","otherNames":[]},{"type":"BIOLOGICAL","name":"infliximab","otherNames":[]},{"type":"BIOLOGICAL","name":"infliximab","otherNames":[]}],"arms":[{"label":"002","type":"EXPERIMENTAL"},{"label":"001","type":"EXPERIMENTAL"}],"summary":"The purpose of the study is to evaluate the effectiveness and safety of infliximab (Remicade) in children with moderately to severely active ulcerative colitis.","primaryOutcome":{"measure":"The Number of Participants With Clinical Response at Week 8","timeFrame":"Week 8","effectByArm":[{"arm":"Infliximab 5 mg/kg","deltaMin":44,"sd":null}],"pValues":[]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":27,"countries":["United States","Belgium","Canada","Denmark","Netherlands"]},"refs":{"pmids":["29925913"],"seeAlso":["http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_JNJ_6051&studyid=174&filename=CR012388_CSR.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":15},"commonTop":["Colitis Ulcerative","Upper Respiratory Tract Infection","Pharyngitis","Abdominal Pain","Fever"]}}